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Abstract
Background: The National Cancer Institute-60 (NCI-60) cell lines are among the most widely used models of
human cancer. They provide a platform to integrate DNA sequence information, epigenetic data, RNA and protein
expression, and pharmacologic susceptibilities in studies of cancer cell biology. Genome-wide studies of the
complete panel have included exome sequencing, karyotyping, and copy number analyses but have not targeted
repetitive sequences. Interspersed repeats derived from mobile DNAs are a significant source of heritable genetic
variation, and insertions of active elements can occur somatically in malignancy.
Method: We used Transposon Insertion Profiling by microarray (TIP-chip) to map Long INterspersed Element-1
(LINE-1, L1) and Alu Short INterspersed Element (SINE) insertions in cancer genes in NCI-60 cells. We focused this
discovery effort on annotated Cancer Gene Index loci.
Results: We catalogued a total of 749 and 2,100 loci corresponding to candidate LINE-1 and Alu insertion sites,
respectively. As expected, these numbers encompass previously known insertions, polymorphisms shared in
unrelated tumor cell lines, as well as unique, potentially tumor-specific insertions. We also conducted association
analyses relating individual insertions to a variety of cellular phenotypes.
Conclusions: These data provide a resource for investigators with interests in specific cancer gene loci or mobile
element insertion effects more broadly. Our data underscore that significant genetic variation in cancer genomes is
owed to LINE-1 and Alu retrotransposons. Our findings also indicate that as large numbers of cancer genomes
become available, it will be possible to associate individual transposable element insertion variants with molecular
and phenotypic features of these malignancies.
Significance statement
Transposable elements are repetitive sequences that com-
prise much of our DNA. They create both inherited and
somatically acquired structural variants. Here, we describe
a first generation map of LINE-1 and Alu insertions in
NCI-60 cancer cell lines. This provides a resource for dis-
covering and testing functional consequences of these
sequences.
Background
The National Cancer Institute-60 (NCI-60) cell panel was
developed in the 1980s as a tool for pharmacologic
screens and has become the most extensively studied col-
lection of human cancers [1]. The panel comprises 59 cell
lines encompassing nine tissue origins of malignancy,
including blood, breast, colon, central nervous system,
kidney, lung, ovary, prostate, and skin [2]. They have be-
come a resource for high throughput characterizations
and systems biology based approaches to cancer.
NCI-60 cell genomes have been described by targeted
[3] and whole exome sequencing [4], karyotyping [5], and
assays to detect copy number alteration [6], loss of hetero-
zygosity [7], and DNA methylation [8]. Large scale mRNA
[9] and microRNA [10] expression, protein abundance
[11] and phosphorylation [12], and metabolomic [13]
studies have also been conducted. Because assays are
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applied across the panel of cell lines in each case, datasets
from orthogonal studies can be related to one another.
For example, gene expression patterns have been found to
be predictive of chemotherapeutic sensitivities [9].
Interspersed repeats have not been incorporated in
these or many other genome-wide surveys. These repeti-
tive sequences are dynamic constituents of human ge-
nomes and important sources of structural variation
[14–20]. RNA transcribed from active elements can be
reverse transcribed and integrated into the genome at
new sites by proteins encoded by LINE-1 (Long INter-
spersed Element)-1 [21–23]. The result is that relatively
recent insertions of LINE-1 (L1Hs) and Alu SINEs
(AluYa5, AluYa8, AluYb8, AluYb9) are sources of genetic
polymorphisms where both the pre-insertion allele and
the insertion allele coexist in human populations. More-
over, LINE-1 sequences are hypomethylated [24–28] and
express protein in a wide variety of human cancers [29],
and somatic LINE-1 integrations have been reported in
tumor genomes [15, 30–36].
It is well established that inherited and acquired mo-
bile DNA insertions can affect gene expression; there is
inherent potential for insertions to have effects on tumor
biology. However, the large majority occur in intronic or
intergenic regions. Strong biases in the distribution of
insertion sites or recurrent ‘hotspots’ for insertions aris-
ing during tumor development are frequently not obvi-
ous, leading to the presumption that most are non-
functional ‘passenger mutations’ [34, 36].
This is not such a tumor-normal comparison study,
but rather, one aimed to identify potential functions of
mobile DNAs in human cancer cells. Towards this end,
we mapped LINE-1 and Alu insertions in the NCI-60
tumor cell panel. We used a method for interspersed re-
peat mapping, Transposon Insertion Profiling by micro-
array (TIP-chip), to identify insertion sites. We also use
Fig. 1 Mapping transposable element (TE) insertion sites. a. A schematic illustrating the sequential steps of Transposon Insertion Profiling by
microarray (TIP-chip). (1) An interval of double stranded genomic DNA with two TE insertions (boxes) oriented on opposing strands is shown; (2)
the DNA is digested in parallel restriction enzyme reactions and ligated to vectorette oligonucleotides; (3) oligonucleotides complementary to the
TE insertions prime first strand synthesis; (4) the elongating strands form reverse complements of the vectorette sequence; (5) there is
exponential amplification of insertion site fragments; (6) these amplicons are labeled and hybridized to genomic tiling microarrays; and (7) ‘peaks’
of fluorescence intensity across several probes corresponding to contiguous genomic positions indicate a TE insertion. b. An example of a
polymorphic Alu peak in two leukemia cell lines (SR and MOLT-4) in the third intron of the TCOF1 (Treacher Collins-Franceschetti syndrome 1)
gene on chromosome 5. The upper panels show TIP-chip data for the insertion, which is present in the SR line and not the MOLT-4 cells. The Alu
insertion is a minus (-) strand insertion to the right of the probe with the greatest intensity; an arrow is drawn to indicate its position and orienta-
tion, but the arrow is not drawn to scale. Alu insertions approximate 300 bp, and the width of the peak in this case is 5 kb. c. Peaks were recog-
nized using a sliding window algorithm which identified adjacent probes above a threshold fluorescence intensity value. The threshold value was
progressively lowered to identify peaks in a rank order. The graphs show the number of reference insertions identified verses peak rank for a rep-
resentative LINE-1 and Alu TIP-chip. The cut-off for defining a candidate insertion was established using the inflection points (red arrows) of
these plots
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previous characterizations of the cell panel to associate
specific insertions with cellular phenotypes.
Results
Transposon insertion profiling by microarray
To map mobile DNA insertions, we used a method we
have termed transposon insertion profiling by micro-
array (TIP-chip), which uses vectorette PCR to amplify
unknown sequence adjacent to a known primer-binding
site (Fig. 1a). We surveyed three major currently active
mobile DNAs in humans (L1Hs, AluYa5/8; and AluYb8/
9) as previously described [14]. To focus on the potential
functional impact of these sequences on cancer cell phe-
notypes, PCR amplicons were labeled and analyzed using
a genomic tiling microarray designed to encompass
6,484 known Cancer Gene Index loci (+/- 10 kb) (Bio-
max™ Informatics), about 17 % of the genome. Peaks of
signal intensity correspond to TE insertions (Fig. 1a, b);
known LINE-1 and Alu elements incorporated in the
reference genome assembly (hereafter, ‘reference inser-
tions’) were used as a quality control metric and to set
cut-offs for recognized peaks (Fig. 1c).
Fig. 2 Total TE insertions. The stacked bar plots show the relative numbers of novel variants, known variants, and reference insertions per cell line
for LINE-1 (green, upper panel) and Alu (red, lower panel). The total number of insertions detected per cell line is similar across the tumor panel
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A total of 749 and 2,100 peaks corresponding to candi-
date LINE-1 and Alu insertion sites respectively were
recognized across the NCI-60 cell panel. These locations
were cross-referenced to previously described insertions
to define three categories: (i.) reference insertions, which
include invariant insertions and insertion polymor-
phisms incorporated in the reference genome assembly;
(ii.) inherited variants either previously described
(known polymorphic) or newly discovered, but occurring
in multiple, unrelated cell lines (novel polymorphic); and
(iii.) novel, ‘singleton’ insertions seen uniquely in one cell
line (Fig. 2a, b). The last category includes both inser-
tions that were constitutive (germline) in the patient
from whom the cell line was derived as well as somatic
insertions acquired during tumor development or the
propagation of these cell lines. A greater proportion of
LINE-1 insertions were singletons (68 %) compared with
Alu insertions (21 %). Density plots for both LINE-1 and
Alu show most peaks fall into this last category, particu-
larly for L1Hs, although a biphasic distribution was seen
(Fig. 3a, b).
Our array encompassed 130 known reference LINE-1
and 1278 Alu insertions. A total of 112 LINE-1 and
1,160 Alu insertions detected were present in the refer-
ence genome assembly. A total of 697 LINE-1 and 1,147
Alu insertions were singleton or polymorphic (known
and novel) segregating in human populations (Fig. 2a,
b). Insertions incorporated in the reference genome that
are known to be polymorphic are counted in both
groups. A summary of insertion positions by tumor type
and cell line can be found in Additional file 1: Table S1,
Additional file 2: Table S2.
We found that each cell line had a unique transposable
element (TE) insertion profile (Fig. 3a). After correcting
for batch effects, a principal component analyses (PCA)
did not show clustering by tumor type. As expected,
however, pairs of cell lines derived from the same indi-
vidual grouped together, and these pairs showed a high
concordance of top-ranking peaks as compared to unre-
lated cell lines. We compared TE insertion profiles to
described cytogenetic abnormalities. In some instances,
insertions were informative of deletions; for example, a
reference LINE-1 in the retinoblastoma 1 (RB1) locus
was only absent in the MB468 breast cancer cell line,
consistent with the homozygous deletion of RB1 re-
ported for this cell line [37].
Insertions in genes involved in oncogenesis
In TIP-chip, probe spacing does not resolve insertions to
the precise base, and insertion strandedness was not pre-
dicted for all peak intervals in this study. Despite these
limitations, we identified peak intervals that partially or
entirely overlapped exon intervals for further inspection.
Partial overlaps were almost entirely attributable to in-
sertions near an exon. We identified 9 insertions within
exons, and all were located within gene 3’ untranslated
regions (3’ UTRs); none affected protein open reading
frames.
Fig. 3 Distribution of TE insertions across the NCI-60 panel. a. Individual insertions are arrayed in order of frequency horizontally, and cell lines are
arrayed vertically. Yellow denotes presence of insertion; blue denotes absence. LINE-1 are on the upper plot, and Alu are on the lower. Cell types
are listed for the lower panel, and the ordering is the same in the upper panel. b. The density plot shows proportions of insertions against the
numbers of cell lines containing an insertion. For both Alu (red) and LINE-1 (green), there is a bimodal distribution. The leftmost density reflects a
large number of polymorphic insertions with low allele frequencies and (for LINE-1 singletons) somatically acquired insertions. The rightmost in-
crease in density shows common variants or fixed insertions present in most or all cell lines
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To begin to approach potential functional conse-
quences of intronic insertions, we analyzed insertion
sites in sets of genes with described roles in cancer. We
considered collections of genes with TE insertions while
grouping together malignant cell lines by tissue of origin.
Interestingly, in breast cancer cell lines, we observed a
significant enrichment of singleton and polymorphic
LINE-1 and Alu insertions in “STOP genes”, defined in
shRNA screens as suppressors of human mammary epi-
thelial cell proliferation [38] (p = 1.23x10-9) (Fig. 4a).
This result persisted when LINE-1 and Alu insertions
were analyzed independently; LINE-1 singleton inser-
tions but not Alu singleton insertions were also enriched
in this gene set (Fig. 4b). Analysis of expression of these
“STOP” genes shows that a preponderance of these
genes are down-regulated; this result persists in those
genes containing a TE insertion. The findings suggest
that collectively, insertions may act to compromise ex-
pression of these genes.
Consistent with this model, ovarian cancer cell lines
showed a preponderance of insertions in genes that are
down regulated in ovarian cancers as compared to nor-
mal tissue. A random set of genes from the array is
shown as a histogram for comparison (Fig. 4d). This pat-
tern was absent in other tumor types.
We saw an enrichment of singleton and polymorphic
TEs in genes recurrently mutated in experimental cancer
models and in human tumors. For the former, we con-
sidered common insertion sites (CIS) defined as gene
loci recurrently interrupted by insertional mutagens in
forward cancer gene screens in mice [39, 40] (p =
1.46x10-4). The latter was assessed using genes fre-
quently mutated in human cancers taken from the Cata-
logue Of Somatic Mutations In Cancer (COSMIC)
database [41] (p = 7.74x10-10) (Fig. 4c). We also com-
pared our insertion profiles to sites of reported somatic
TE insertions in human cancers. We analyzed novel
(singleton and polymorphic) insertions and discovered
that we had overlaps in 22 of the 64 genes noted by Lee
et al. [32] and 23 of 76 from Solimini et al. [38](Fig. 4c).
We anticipate the possibility that common insertion site
loci will be identified as more insertion site mapping
studies are conducted in human tumors.
Functional associations of individual insertions
An advantage of working with the NCI-60 cell lines is that
these are well studied. To integrate our insertion site maps
with other findings in these cells, we performed COM-
PARE analyses [42]. COMPARE is a pattern matching
method developed specifically for NCI-60 cell lines that
provides a p-value for each association (S5–25). Direct,
local roles for TEs (in cis) were not observed for the ma-
jority of correlations. However, COMPARE did reveal
three insertions associated with DNA hypermethylation
Fig. 4 TE enrichment analyses. a. STOP and GO genes have been implicated in breast cancer as genes that appear to inhibit and promote tumor
development, respectively. Using a hypergeometric distribution to assess enrichment, we found that TE insertions are enriched in STOP genes on
the array (p = 1.23x10-9) but not in GO genes (p = 0.33). b. The bar graph shows enrichment by type of TE plotted as the negative log of the
p-value. No GO gene enrichment is seen. STOP gene enrichment is seen considering all LINE-1 (p = 3.11x10-3); all Alu (p = 2.27x10-10); as well as
LINE-1 singletons (p = 4.16x10-5). c. Insertions were also enriched in common insertion sites (CIS) (p = 1.46x10-4); COSMIC commonly mutated
cancer genes (p = 7.74x10-10); and genes reported to acquire somatic LINE-1 insertions in cancer by Lee et al. (p = 5.34x10-14). d. Genes with TE
insertions in ovarian cancer cell lines are more likely than other genes to be downregulated in ovarian cancer samples as compared to normal
tissue controls. Randomly selected genes are shown for comparison (bottom panel)
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within 30 kb of the insertion site. For example, a poly-
morphic Alu insertion in the SS18L1 (Synovial sarcoma
translocation gene on chromosome 18-like 1) gene locus
oriented anti-sense to the transcription of the gene, is
associated with increased methylation of nearby CpG sites
at the same gene locus (p = 6.67x10-6) (Fig. 5a).
Manhattan plots illustrate highly significant correla-
tions found in trans (Fig. 5a–c). A subset of insertions
Fig. 5 TE insertions associated with cellular phenotypes. a. Associations with DNA methylation. (Upper panel) Diagram of the SS18L1
(Synovial sarcoma translocation gene on chromosome 18-like 1) gene locus, which contains an antisense Alu associated with increased
CpG methylation at that gene (i.e., in cis, p = 3.67x10-6) (Middle panel) Manhattan plot showing TE positions on the x-axis and strengths of
association with gene methylation on the y-axis (Bonferroni-corrected p-values). Singleton insertions were excluded from association
analyses. Gene abbreviations are given for both the gene in which the insertion is found (red) and the associated methylation site (black)
in examples. The TE insertion at the CSRP2 (cysteine and glycine-rich protein 2) gene locus was associated with methylation at 22 distinct
loci (Lower panel). The associated methylation sites are distributed throughout the genome. b. Manhattan plot showing associations with steady state
mRNA levels. Gene abbreviations are given for both the gene in which the insertion is found (red) and the associated transcript level (black); in these
two examples, the TE is associated with upregulation of the mRNA. c. Manhattan plot showing associations with drug sensitivity as measured by total
cellular growth inhibition. The gene in which the insertion is found is given (red), as well as the associated pharmacologic agent (black)
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had multiple associations (vertical series of dots corre-
sponding to one TE location), suggesting the possibility
of pleomorphic effects of an insertion haplotype.
In addition, we encountered examples of single ‘driver’
mutations and cellular phenotypes that could be associ-
ated with multiple TE insertions. Five insertions correlated
with a mutation in the ERBB2 gene (v-erb-b2 erythro-
blastic leukemia viral oncogene homolog 2, the HER2/neu
locus), and more than 10 insertions were associated with
thymidylate synthase activity (p values < 10-20). To probe
relationships between multiple trans associated factors re-
lated to a single TE insertion, we performed pathway ana-
lyses on sets of genes, each encompassing the TE insertion
locus and all RNAs and proteins with associated expres-
sion patterns. This yielded more than 250 curated path-
ways with enrichment p-values less than 10-4, supporting
the concept that these are biologically relevant as opposed
to spurious associations. All COMPARE results are pro-
vided in the (Additional file 3: Table S3).
Discussion
Our genomes are filled with highly repetitive DNA se-
quences derived from TEs. Tailored methods for their
detection, including TIP-chip [14], targeted insertion site
sequencing [15, 17, 18, 31, 36, 43], and algorithms for
finding variants in whole genome sequencing [20, 34,
44] are revealing this previously masked dimension of
genomic data. Collectively, these studies confirm that
TEs are rich sources of genetic diversity in human popu-
lations, and provide evidence that they are somatically
unstable in a variety of tumor types. Of the two most ac-
tive germline elements, LINE-1 and Alu, (which is mobi-
lized in trans by LINE-1-encoded proteins), LINE-1 has
been more well documented to be active in cancer. Alu
insertions account for more inherited polymorphisms.
For both types of TEs, the vast majority of catalogued
insertions are intronic and intergenic without clear
function.
To begin a systematic survey for functionally conse-
quential LINE-1 and Alu integrations in human neopla-
sias, we mapped these variants in the NCI-60 cell panel.
NCI-60 is a unique resource for this, encompassing a
variety of cancer cell lines that have the advantages of
being well studied and readily available. We mapped
LINE-1 and Alu insertion positions using a microarray-
based approach over a large census of cancer genes.
Even as TIP-chip is replaced by sequencing, we expect
these data will provide a useful reference.
TIP-chip across the NCI-60 panel revealed numerous
novel candidate TEs, totaling about 500 L1Hs and 1000
AluYa/Yb insertions distributed across the 60 cell lines.
These include insertions that are unique to a cell line
(‘singleton’) and novel polymorphic insertions (found in
unrelated cell lines). Although ‘singletons’ may be
enriched for tumor-specific, somatic insertion events,
matched non-neoplastic cells for the corresponding pa-
tient cases are not available, and therefore we cannot de-
finitively differentiate somatic from inherited variants.
Similarly, these cell lines have undergone numerous pas-
sages since their creation, and somatic insertion events
occurring in culture cannot be clearly recognized. We
note a greater proportion of LINE-1 singletons (68 % of
LINE-1 loci) than Alu singletons (21 % of Alu loci), con-
sistent with ongoing LINE-1 retrotransposition in vivo
or in vitro.
We approached the question of TE function by two
avenues. We first tested for biases in the distribution of
insertions with respect to known gene sets. We found a
preferential accumulation of TE insertions in retained
copies of ‘STOP genes’ in breast cancer cell lines; these
gene loci function as inhibitors of mammary epithelial
cell proliferation. Experimental models suggest that it is
advantageous for tumor growth to compromise the
function of these genes [38], and we speculate that TE
insertions are enriched at these loci because they have a
role in this process. These ‘STOP genes’ are downregu-
lated in the breast cancer cell lines, as is the subset of
‘STOP genes’ containing TE insertions. We also found
preferential TE accumulation in genes downregulated in
ovarian cancers compared with normal ovarian tissue,
which would be consistent with this model. Finally,
genes with functional roles in cancer were also more
commonly seen as insertion sites than expected. These
included genes ‘hit’ recurrently by insertional mutagen-
esis in forward genetics screens in mice, the so-called
common insertion sites (CIS), and in genes commonly
mutated in human cancers (COSMIC catalog) [41].
We note that the exonizations of intronic LINE-1
[45] and Alu sequences [46] are being increasingly
recognized using RNA-seq, and that many of the
resulting transcripts have an altered protein coding
capacity. It may be possible to identify aberrant
mRNA species corresponding to these insertion loci
and thus invoke a molecular mechanism to underlie
this type of functional effect.
Our second approach relied on association studies.
We used existing data in COMPARE analyses to test for
relationships between TE insertion alleles and cellular
phenotypes. In the case of DNA methylation only, cis ef-
fects could be seen relating individual TEs with local
DNA hypermethylation. We identified three Alu integra-
tions associated with DNA hypermethylation at the in-
sertion site (+/- 30 kb). The most notable is a
polymorphic Alu insertion in the first intron of the
SS18L1 (synovial sarcoma translocation gene on
chromosome 18-like 1) gene locus associated with CpG
hypermethylation at the same locus (p = 3.67x10-6). SS18
and SS18L1 encode transcriptional regulators and are
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breakpoints in chromosomal translocations in synovial
sarcoma [47]. These translocations are not seen in the
NCI-60 panel tumors, and whether the epigenetic signa-
ture associated with the Alu insertion impacts expres-
sion of this gene is unknown. So, while it is not clear at
this point that SS18L1 methylation is germane to the de-
velopment of these malignancies, our ability to relate
genotype and epigenetics at these sites demonstrate the
value of this approach.
The large majority of statistically significant associa-
tions between insertions and cellular phenotypes ap-
peared to involve indirect or trans effects that are
difficult to test further. Pathway analyses suggest that
many are not random, but reflect recognized, related
gene sets. It may be that the indirect effects can be dis-
sected for some insertion alleles; particularly promising
may be those at loci of transcriptional regulators with
definable target genes [29].
Conclusions
In summary, we profiled LINE-1 and Alu insertion sites
in a panel of widely used cancer cell lines, the NCI-60.
We expect maps such as these will be a useful resource
for experimentalists with interests in how transposable
element insertions interact with genes. Our analyses
show that insertion sites can be integrated with other
data to develop testable hypotheses about the function
of mobile DNAs in cancer.
Methods
NCI-60 cell lines
The National Cancer Institute-60 (NCI-60) human can-
cer cells are a group of 60 cell lines representing nine
different types of neoplasias(breast cancer, colon cancer,
CNS tumor, leukemia, lung cancer, melanoma, ovarian
cancer, prostate cancer, and renal cell carcinoma) com-
posed of 54 individual cancer cases and three pairs of
cell lines (ADR and OVCAR-8; MB-435 and M14; and
SNB19 and U251) with each pair originating from the
same patient [48, 49]. The NCI-60 panel has been exten-
sively characterized in a breadth of molecular and
pharmacologic assay [50]. Genomic DNA was obtained
directly from the NCI.
Microarray design
A genomic tiling micorarrray was designed to cover the
NCI Cancer Gene Index (disease list). A total of 6,484
RefSeq gene identifiers were extracted from the. XML
file and converted to genomic coordinates corresponding
to each transcript unit +/- 10 kb hg19 reference genome
assembly (February 2009, GRCh37). UCSC Table
Browser intervals were merged using GALAXY [51], and
probes were chosen for the NimbleGen HD (2.1 M
feature) array platform by the manufacturer (Roche
NimbleGen, Madison, WI).
Transposon insertion profiling by microarray (TIP-chip)
Five micrograms of genomic DNA of each cell line was
digested overnight in parallel reactions using four re-
striction enzymes (AseI, BspHI, HindIII, and Xbal).
Sticky ends were ligated to annealed, partially comple-
mentary vectorette oligonucleotide adapters. Each tem-
plate was aliquoted into 3 separate vectorette PCR
reactions for L1Hs, AluYa5/8, and AluYb8/9 mobile
DNA families. These were then labeled with Cy3-dUTP
for LINE-1 and Cy5-dUTP for Alu and hybridized to
Nimblegen genome tiling arrays according to the manu-
facturer’s instructions. Reference insertions are those in-
corporated in the Feb. 2009 assembly of the human
genome (hg19, GRCh37 Genome Reference Consortium
Human Reference 37, GCA_000001405.1).
Peak recognition
Each scanned array yielded a raw .tff file, which was
processed using Nimblescan v2.5 (Roche Nimblegen,
Madison, WI) to give genomic coordinates and probe in-
tensities (.gff files). A PERL script removed probes over-
lapping repeats to reduce noise (RepeatMasking).
Nimblescan called peaks using a sliding window thresh-
old. Peaks were ranked by the threshold of the log2
transformed ratio of red (Alu) and green (L1) channels
or the reciprocal (settings: percent (p) start = 90, p step
= 1, #steps = 76, width of sliding window = 1500 bp, min
probes > 4, all probes > 2). The top 5,000 L1 and Alu
peaks were kept for evaluation.
Peak cut-off
Among these peaks, recovery of those corresponding to
mobile DNA insertions in hg19 (reference insertions)
was used as a proxy of assay performance. Reference in-
sertion count was plotted against peaks recognized
(Fig. 1c). A cut-off was imposed on the peak threshold
value (p >70 for L1 and p > 60 for Alu) to include peaks
up to the approximate inflection point of this curve in
subsequent analyses. These threshold values were altered
for outlier cell lines to reflect the curve inflection point.
MYSQL was used to annotate peaks with respect to
genes and known mobile DNA insertions (L1Hs, AluY,
AluYa5, AluYa8, AluYb8, and AluYb9 using 1−2 kb mar-
gins). Lists of known insertions were obtained from pre-
viously published databases [14, 19, 52, 53].
Clustering and insertion profiles
Principle component analysis (PCA) (R-package) was
used to remove batch effect. All insertions were sorted
by density across the cell lines and plotted as a matrix.
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Cell lines lacking high-frequency insertions were
assessed for karyotype abnormalities manually.
COMPARE analysis
Reference and non-reference insertions were analyzed
using a COMPARE analysis [42] associating each with
the CellMiner database of NCI-60 cell profiling studies.
These have included DNA mutations and methylation;
RNA and miRNA expression; protein expression, en-
zymatic activity; and drug inhibition studies. Associa-
tions for those insertions found in one cell line
(singleton) were considered only for cis effects and were
discarded from other associations due to their high
false-positive rates. P-values for other insertions were
corrected using Bonferroni multiple test correction and
plotted using the start position of peak intervals to gen-
erate Manhattan plots (adaptation of Genetics Analysis
Package, R-package).
Pathway analysis
Gene loci containing candidate non-reference (poly-
morphic and singleton) LINE-1 and Alu insertions and as-
sociated gene names from RNA and protein COMPARE
analysis were uploaded in batch to the MSigDb ‘Investi-
gate Gene Sets’ from the Broad Institute Gene Set Enrich-
ment Analysis web interface [54] (using the C2 curated
gene sets). Pathways were selected if the insertion locus
was part of the pathway and the p-value of the pathway
was less than 10-4. Interactome plots were used to
visualize relationships between genes in pathways using
Search Tool for the Retrieval of Interacting Genes/Protein
(STRING) 9.0 [55]. Plots were adapted to show the gene
locus containing the insertion (yellow) and the direction
of related correlations (red for positive correlations with
the insertion; purple for negative correlations).
Preferential integration sites
To investigate preferential transposable element inser-
tion in genes implicated in oncogenesis and mouse com-
mon insertion sites, we used a hypergeometric
distribution test (pHypr R-package) which controlled for
genes tiled on the array. Results were plotted using the
–log(p-value).
Tumor-normal gene expression studies
Tumor vs normal gene expression for genes containing
candidate non-reference TE insertions was assessed for
each tumor type using large tumor/normal gene expres-
sion databases. Tumor gene to normal gene expression ra-
tios were obtained using NCBI GEO2R [56]. GEO2R was
used to log2 transform expression data if datasets were
not in log2 formats. Value distribution of all databases was
assessed for median-centering prior to evaluation. Expres-
sion values for all insertion-containing genes was plotted
as a horizontal bar plot. A random sample of 1000 genes
from the array were evaluated in the same manner to
serve as a control set. A histogram of random gene ex-
pression values was plotted. Databases (Breast = GSE5764,
Ovarian =GSE26712, omitted samples with “no evidence
of disease”, Colon =GSE6988, omitted non-primary tu-
mors, Melanoma =GSE7553, CNS =GSE4290, non-tumor
used as “normal” and non-glioblastomas omitted, Prostate
= GSE3325, Renal = GSE11151, non-conventional tumors
omitted, NSCL =GSE19188).
STOP gene expression in breast cancer cell lines
Expression of STOP genes containing candidate non-
reference TE insertions was assessed using log2 trans-
formed Agilent mRNA expression data [57] obtained
from the CellMiner for the Breast cancer cell lines. The
expression was averaged across all cell lines, sorted, and
plotted as a horizontal bar plot. STOP genes tiled on the
array, but without a TE insertion was plotted as well.
Tumor-Normal expression for STOP genes was per-
formed according to the methods used above in Tumor-
Normal gene expression studies.
Additional files
Additional file 1 A map of LINE-1 (L1) insertion site positions in the
NCI-60 cell panel. Genomic coordinates of TIP-chip peaks are provided.
Reference insertions are indicated in column D (hg19), and known poly-
morphic variants are indicated by a ‘Y’ in column E (Y/N, yes/no). For
each cell line in columns G-BN, a ‘1’ indicates that the insertion is present,
while ‘0’ indicates that the insertion is not found. (XLSX 85 kb)
Additional file 2 A map of Alu insertion site positions in the NCI-60 cell
panel. Genomic coordinates of TIP-chip peaks are provided. Reference in-
sertions are indicated in column D (hg19), and known polymorphic vari-
ants are indicated by a ‘Y’ in column E (Y/N, yes/no). For each cell line in
columns G-BN, a ‘1’ indicates that the insertion is present, while ‘0’ indi-
cates that the insertion is not found. (XLSX 380 kb)
Additional file 3 COMPARE analysis associating insertions with other
cell characteristics. Different tabs are used for different datasets. Activity,
enzyme activity measures; Decreased / Increased methylation, DNA
methylation measures; Metabolome, metabolic intermediates; Drug Effect
GI50, concentration for 50 % growth inhibition; Drug Effect TGI,
concentration for total growth inhibition; miRNA, microRNA expression
levels; RNA, mRNA expression levels; Mutations, somatically-acquired DNA
mutations; Protein, protein expression. (XLSX 4049 kb)
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